Danaher Corporation (DHR)
Danaher Corporation (DHR) is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and consumer products and services. Founded in 1984, the company operates through various segments, including life sciences, diagnostics, and environmental & applied solutions, serving customers in health, environmental, and industrial markets worldwide. Danaher is known for its focus on continuous improvement and leveraging science and technology to solve complex problems.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 31, 2025 | $0.32 | 2025-09-26 | 2025-09-26 |
| July 25, 2025 | $0.32 | 2025-06-27 | 2025-06-27 |
| April 25, 2025 | $0.32 | 2025-03-28 | 2025-03-28 |
| January 31, 2025 | $0.27 | 2024-12-27 | 2024-12-27 |
| October 25, 2024 | $0.27 | 2024-09-27 | 2024-09-27 |
Dividends Summary
- Danaher Corporation has issued 88 dividend payments over the past 21 years
- The most recent dividend was paid 21 days ago, on October 31, 2025
- The highest dividend payed out to investors during this period was $0.32 per share
- The average dividend paid during this period was $0.11 per share.
Company News
Activist investor Dan Loeb's Third Point LLC significantly increased stakes in big tech stocks like Microsoft and Meta while completely exiting positions in companies like Workday during Q3 2025.
Questex's Fierce Biotech and Fierce Pharma announced the 2025 Life Sciences Innovation Awards, recognizing groundbreaking companies across various technological domains in healthcare and biotechnology.
Danaher reported strong Q3 earnings with core revenue growth of 3% and an adjusted operating profit margin of 27.9%, exceeding expectations. The company's performance was driven by strong bioprocessing business and better-than-anticipated respiratory revenue at Cepheid.
Danaher Corporation reported strong Q3 2025 financial results, with revenues of $6.1 billion (4.5% increase) and adjusted earnings per share of $1.89, exceeding market expectations. The company maintained its full-year earnings guidance and demonstrated robust cash generation and strategic execution.
The article discusses the latest research reports on Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals, and Oil-Dri. It highlights the key strengths and challenges faced by these companies.
